Soliton – The Great Reg A+ IPO P&D PR...
Summary Soliton is a Reg A+ IPO, which means they could not get institutional investors, so they had to raise...
Research
(If you're unable to access an article, contact us and we'll email you the full article)
The FDA Might Have Inadvertently Implanted Establishment Labs As...
Establishment Labs (ESTA) has taken the breast implant industry by storm with its next level technology, 6th generation, Motiva Implants....
Torchlight Energy: We Believe Its Orogrande Project Is Worthless,...
Torchlight Energy has an enterprise value of over $130M. The company's entire perceived value is based on possible oil in...
Conformis Is A Failed Market Experiment, No Justification For...
We believe the 400% appreciation of Conformis (CFMS) in 2019 is not from any positive fundamental developments, but from hype...
American Superconductor Is A House Of Cards Set To...
American Superconductor stock has risen over 100% since July 2018 on little progress in its businesses. We expect a fade...
Why Hospitals Are Not Buying T2 Biosystems Diagnostic System...
T2 Biosystems’ recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition,...
Apyx Medical Is About To Have A Liposuction –...
Apyx is a provider of J-Plasma technology that has failed every medical application and is now only targeted for two...
New Age Beverages Is About To Take A Spill...
NBEV is a $500M market cap struggling US beverage roll-up attempting to reinvent itself by marketing CBD-infused drinks The Company’s...
FSD Pharma: A Rollup With Scattered, Uneconomical Cannabis Investments,...
FSD Pharma’s founder, Thomas Fairfull, and director, Anthony Durkacz, have a history of value destruction. Durkacz had an average loss...
Helius Medical: A Failed Clinical Trial, Redacted Data, And...
Helius Medical is a reverse-merger, single-product, pre-revenue medical device company with a unique device that delivers stimulation to the tongue...
Orchids Paper: Toliet Paper Never Looked So Dirty –...
Each 2018 quarter, Orchids Paper (TIS) has had a consecutively worse financial performance. For the past two quarters, Orchids' gross...
Transenterix: Surgical Robot Experts Call Its Senhance System ‘A...
TransEnterix (TRXC) was originally funded by a notorious investor recently charged by the SEC for orchestrating pump and dumps. A...
Track Record
We have an over 90% success rate
3rd Party Verified:
(click on the stock symbols below to see the reports)
Get Our Latest Reports Delivered To Your Inbox (we will not share your email with anyone)